Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation–positive metastatic melanoma treated with vemurafenib ± cobimetinib

Overview of attention for article published in European Journal of Cancer (1965), June 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 12 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 2,197 followers.

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib. https://t.co/I0ReqTk3tY

08 Jun 2019

Reply Repost Favourite

RT @PAscierto: Effect of concomitant dosing with acid-reducing agents and vemurafenib... https://t.co/8PQUohSslw

05 Jun 2019

Reply Repost Favourite

Effect of concomitant dosing with acid-reducing agents and vemurafenib... https://t.co/8PQUohSslw

05 Jun 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.